StemCells Inc Share Price Nasdaq
Stocks
US85857R2040
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 117M 101M 94.6M 86.28M 162M 11.11B 165M 1.11B 435M 5.57B 438M 428M 18.56B | P/E 2026 * |
-6.05x | P/E 2027 * | -6.12x |
|---|---|---|---|---|---|
| Enterprise Value | 117M 101M 94.6M 86.28M 162M 11.11B 165M 1.11B 435M 5.57B 438M 428M 18.56B | EV / Sales 2026 * |
46.6x | EV / Sales 2027 * | 11.1x |
| Free-Float |
100% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: StemCells Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Harel Gadot
CEO | Chief Executive Officer | 54 | 01/08/1988 |
Rachel Vaknin
DFI | Director of Finance/CFO | 47 | 31/03/2022 |
Michal Ahuvia
COO | Chief Operating Officer | - | 20/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Harel Gadot
CHM | Chairman | 54 | 31/12/2012 |
Scott Burell
BRD | Director/Board Member | 61 | 27/11/2016 |
Martin Madden
BRD | Director/Board Member | 65 | 05/02/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.84% | +1.09% | +4.03% | +15.90% | 48.72B | ||
| +0.24% | +3.34% | +466.72% | +581.38% | 43.99B | ||
| +0.11% | +8.54% | +16.41% | +75.36% | 40.82B | ||
| +0.82% | +3.80% | +26.83% | +9.60% | 39.79B | ||
| -4.04% | +6.15% | +23.03% | +48.00% | 32.7B | ||
| -0.85% | +1.17% | +26.47% | +122.82% | 16.66B | ||
| -3.64% | -1.09% | - | - | 16.84B | ||
| +0.98% | +0.57% | +5.21% | +21.89% | 13.95B | ||
| -0.07% | +6.22% | +81.95% | +30.02% | 13.58B | ||
| Average | -0.55% | +3.96% | +81.33% | +113.12% | 29.67B | |
| Weighted average by Cap. | -0.24% | +3.93% | +99.30% | +136.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.5M 2.17M 2.03M 1.85M 3.48M 238M 3.53M 23.87M 9.33M 119M 9.39M 9.18M 398M | 10.5M 9.1M 8.52M 7.77M 14.62M 1B 14.84M 100M 39.19M 501M 39.42M 38.57M 1.67B |
| Net income | -21M -18.19M -17.05M -15.55M -29.23M -2B -29.68M -200M -78.37M -1B -78.85M -77.13M -3.34B | -19.02M -16.48M -15.44M -14.08M -26.47M -1.81B -26.88M -182M -70.97M -908M -71.4M -69.85M -3.03B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions

















